Zevra Therapeutics Elects New Directors at Annual Meeting

Zevra Therapeutics ( (ZVRA) ) has shared an update.

On May 29, 2025, Zevra Therapeutics held its Annual Meeting of Stockholders where Wendy Dixon, Ph.D., and Tamara A. Favorito were elected as directors. The meeting also saw the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. The election process was marked by the disqualification of nominees proposed by stockholder Daniel J. Mangless due to non-compliance with legal requirements and company bylaws, ensuring the election of the company’s preferred candidates.

The most recent analyst rating on (ZVRA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.

Spark’s Take on ZVRA Stock

According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.

Zevra Therapeutics’ overall score is primarily influenced by strong revenue growth but is hampered by significant profitability and leverage issues. Technical indicators show positive momentum, yet caution is advised due to potential overbought conditions. The valuation remains challenging with ongoing losses, and while the earnings call highlighted strategic progress, market penetration challenges persist.

To see Spark’s full report on ZVRA stock, click here.

More about Zevra Therapeutics

Zevra Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company is primarily involved in creating innovative treatments for various medical conditions.

Average Trading Volume: 543,197

Technical Sentiment Signal: Buy

Current Market Cap: $462M

Learn more about ZVRA stock on TipRanks’ Stock Analysis page.